Sugi Predict

Sugi Predict / Compounds / SCHEMBL277280

SCHEMBL277280

SCHEMBL277280

Cc1ccccc1C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 2/20 0.48
▸ ADRB1 P08588 2/20 0.48
▸ ADRB3 P13945 2/20 0.48
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ ESR1 P03372 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ PLK1 P53350 1/20 0.43
▸ PLK2 Q9NYY3 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ GRM6 O15303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782340 0.88 ADRB2 (0.48) ADRB2ADRB1ADRB3NPC1RAB9A
SCHEMBL109178 0.87 TSHR (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL30111657 0.87 TSHR (0.50) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL28215701 0.86 ADRB2 (0.47) ADRB2ADRB1ADRB3NPC1RAB9A
SCHEMBL3639048 0.85 MYC (0.42) ADRB2ADRB1ADRB3KMT2ATSHR
Hydrogen Peroxide SCHEMBL29048859 0.85 TSHR (0.48) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL4352323 0.85 MEN1 (0.46) MEN1KMT2AESR1ESR2LMNA
SCHEMBL28213904 0.84 NPC1 (0.47) ADRB2ADRB1ADRB3NPC1RAB9A
SCHEMBL14944464 0.83 ADRB2 (0.44) ADRB2ADRB1ADRB3NPC1RAB9A
SCHEMBL4659047 0.82 NPC1 (0.46) ADRB2ADRB1ADRB3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107848222-B The method of modified olefine polymer is prepared in an extruder 博里利斯股份公司 2019-08-27 — — CN claimed
CN-107848222-A The method for preparing modified olefine polymer in an extruder 博里利斯股份公司 2018-03-27 — — CN claimed
CN-100555476-C No-halogen fire-resistant radiation cross-link wire and preparation method thereof SHENZHEN WOER NUCLEAR MATERIAL (CN) 2009-10-28 — — CN claimed
CN-1758385-A No-halogen fire-resistant radiation cross-link wire and its preparation method SHENZHEN WOER NUCLEAR MATERIAL (CN) 2006-04-12 — — CN claimed
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
EP-4561575-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
EP-4562016-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024026486-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
CN-113754521-B Synthesis process method of avobenzone 马鞍山科思化学有限公司 2023-12-19 — — CN disclosed
CN-113754521-A Synthetic process method of avobenzone 马鞍山科思化学有限公司 2021-12-07 — — CN disclosed
CN-110520168-A Soft polypropylene compositions with improved properties BOREALIS AG 2019-11-29 — — CN disclosed
CN-101107124-A Multilayer structures BOREALIS TECH OY (FI) 2008-01-16 — — CN disclosed
US-20070225296-A1 Arylalkylamine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-09-27 — — US disclosed
US-20070225296-A1 Arylalkylamine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-09-27 — — US disclosed
US-20070194468-A1 Method of preparing organomagnesium compounds LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2007-08-23 — — US disclosed
EP-1757582-A1 ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF TANABE SEIYAKU CO., LTD. (JP) 2007-02-28 — — EP disclosed
CN-1758385-A No-halogen fire-resistant radiation cross-link wire and its preparation method SHENZHEN WOER NUCLEAR MATERIAL (CN) 2006-04-12 — — CN disclosed
CN-1119434-A Phenoxyphenylacetic acid derivatives MERCK & CO INC (US) 1996-03-27 — — CN disclosed
US-4526882-A Contacting magnesium alcoholate and group II or group IIIA metal alkyl, treating with titanium halide and electron donor, comminuting, treating product with titanium halide, ethyl benzoate, aromatic acid ester STANDARD OIL COMPANY (INDIANA) (US) 1985-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 ADRB2 2721/4885ADRB1 3187/4885ADRB3 3545/4885
US-20070194468-A1 Method of preparing organomagnesium compounds SCLY, LIG3, LIG4 ADRB2 4713/4885ADRB1 4644/4885ADRB3 4453/4885
US-20070225296-A1 Arylalkylamine Compound and Process for Preparing the Same CASR, CNR1, CNR2 ADRB2 44/4885ADRB1 38/4885ADRB3 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.